CONCLUSION: A total of 20 patients with chronic diarrhea (chronic enterocolitis, post-resection syndrome) was under clinical observation. In addition to the standard therapy, patients received Enterosgel in a daily dose of 45 g (per 15 g 3 times a day) for 14 days. The control group consisted of 18 patients comparable by primary diagnosis, gender and age. Therapeutic efficiency was evaluated according to the clinical data, coprological studies, dynamics of colonic microflora, endoscopic and histological analyses, immune status-related study and the complex biochemical research. A high clinical efficiency of Enterosgel preparation has been determined and its positive effect on the intestinal mucosa condition, digestion and absorption processes, the composition of small and large intestine-related microflora. The immunomodulative effect has been identified as conditioned by the normalization of eubiosis and the decreased inflammation activity in the intestinal mucosa. There were not revealed any side events and cases of intolerance when using the Enterosgel enterosorbent. Enterosgel is being recommended for a widespread use in the treatment of chronic digestive diseases that are accompanied by diarrhea syndrome and eubiosis impairment of small and large intestine. A long-term application of Enterosgel is purposeful to get the persistent therapeutic effect.